Sentences with phrase «versus host disease»

Hyperimmune bovine colostrum has been used in clinical trials for treating AIDS - related diarrhea, diarrhea associated with graft versus host disease following bone marrow transplant, and rotavirus diarrhea in children.

Chronic Graft Versus Host Disease: Principles And Practice Of Interdisciplinary Management Cambridge Press; 2009.

Thalidomide is used successfully by Cancer Center researchers to treat graft versus host disease.

The researchers say using the CCR5 mutant donation and / or the presence of graft versus host disease, which results in the elimination of HIV - positive reservoir cells that survive irradiation, played a significant role in curing the Berlin patient.

The favorable results are due in large part to the advances in managing severe graft versus host disease (GVHD), an attack on the patient's normal tissues by immune cells of the donor.

In patients who are cured, the long term side - effects of the chemotherapy and immune suppression treatment as well as any graft versus host disease.

Moreover, there is some evidence that Graft versus Host Disease is more likely where a patient has an older donor, as their cells are more experienced in identifying foreign cells.

Clinical trials have shown promising results for MSCs when applied to treat numerous diseases, such as cardiovascular diseases, brain and spinal cord injury, stroke, diabetes, cartilage and bone injury, Crohn's disease and graft versus host disease (GvHD).

While we know that other donor characteristics can influence the risk of the patient developing Graft versus Host disease or other complications, more research is needed to determine how important different donor factors are on outcomes other than patient survival.»

In spite of mismatching, cord blood cells cause less graft versus host disease (GVHD) than adult cells.

Potentially everyone can benefit from gene modified T cells and there's no danger of graft versus host disease because it's not a transplant from another person.

As expected, xenogeneic graft versus host disease (GVHD), assessed clinically by dermatitis and hair loss, was observed in mice receiving cells treated with both R5 - ZFNs and X4 - ZFNs in the absence of HIV challenge.

While humanized mouse models for HIV infection have utility, the model is limited due to incomplete immune reconstitution, development of xenogeneic graft versus host disease (GVHD), and the absence of normal T cell homeostasis.

A new test may reveal which patients will respond to treatment for graft versus host disease (GVHD), an often life - threatening complication of stem cell transplants (SCT) used to treat leukemia and other blood disorders, according to a study led by researchers at the Icahn School of Medicine at Mount Sinai and published online today in the journal Lancet Haematology and in print in the January issue.

On the flipside, targeting this growth factor or BCL - 2 could reduce NK cell numbers and offer potential therapies for immune disorders such as some types of autoimmune diseases, sepsis or graft versus host disease, a side effect of bone marrow transplants.

Not exact matches

Enlivex is developing a treatment for Graft - versus - Host disease (GvHD) resulting from bone - marrow transplants.

The work was on the role of interleukin - 1 in the pathology of graft - versus - host disease (GVHD), the mechanism by which the new immune system, which a patient receives as a bone marrow transplant, attacks the patient's body following the transplantation.

Results of a Johns Hopkins study may explain why a chemotherapy drug called cyclophosphamide prevents graft - versus - host (GVHD) disease in people who receive bone marrow transplants.

Johns Hopkins Kimmel Cancer Center scientists first used cyclophosphamide to prevent severe graft - versus - host disease (GVHD) after bone marrow transplant involving haploidentical or «half - matched» transplants, a treatment first used in 2000 at the Cancer Center to treat leukemias and other blood cancers.

Historically, clinicians evaluating a patient for transplant have sought to identify donor cells that are perfectly matched to the patient's cell type, which is considered to be the optimal approach to help ensure successful outcomes and to minimize risk of graft - versus - host disease (GVHD), a serious and potentially life - threatening complication that occurs when the donated immune cells attack the patient's cells as foreign tissue.

Hina had developed the devastating immune reaction known as graft - versus - host disease, in which donor cells attack the walls of the gut, skin, lungs, liver, and sometimes — though rarely — even the patient's brain.

The recipients did not suffer from the many common adverse effects of stem transplants, including the grueling graft - versus - host disease, which can cause severe liver damage, rashes, diarrhea and even death.

«Preventing graft - versus - host disease and relapse after transplant requires a difficult balance of eliminating the bad, overactive effector T cells, without suppressing the good, regulatory T cells,» said Kean, who is also an associate professor of pediatrics at the University of Washington School of Medicine and a member of the Fred Hutchinson Cancer Research Center.

«As a transplant physician, it's beyond heartbreaking to witness a patient develop severe acute graft - versus - host disease after having their leukemia cured through bone marrow transplant,» said Kean.

«Given the serious threat of graft - versus - host disease, new approaches to make stem cell transplants safer for patients remain a critical unmet need,» said Dr. Leslie Kean, the trial's principal investigator and associate director of the Ben Towne Center for Childhood Cancer Research at Seattle Children's.

«To have a therapy at our disposal that safely targets just the T cells causing graft - versus - host disease would represent a major step forward in stem cell transplantation.

«Immunotherapy drug nearly eliminates severe acute graft - versus - host disease: Drug used to treat rheumatoid arthritis improves survival after hematopoietic stem cell transplant.»

«Protection for the gut barrier: New approach may prevent graft - versus - host disease: Activating signal paths could protect patients from dangerous immune reactions after stem cell transplantations.»

Graft - versus - host disease is a condition in which the patient's immune system is attacked by the donor stem cells.

Wartman has a chronic form of graft - versus - host disease (GVHD), a debilitating consequence of blood stem cell transplants.

Now, in a study recently published in the journal PLOS ONE, a team of scientists from VCU Massey Cancer Center have shown a genetic relationship between the reactivation of hCMV and the onset of graft - versus - host disease (GVHD), a potentially deadly condition in which the immune system attacks healthy tissue following a bone marrow or stem cell transplant.

Wartman in his lab in March 2011 (left), before he developed chronic graft - versus - host disease, and last month at a physical therapy session (right).

This technology has been developed from a skin explant model for predicting a potentially serious complication of bone marrow transplantation, «graft versus host» disease — a common complication following the transplant.

Scientists in Germany have developed a new approach that may prevent leukemia and lymphoma patients from developing graft - versus - host disease (GvHD) after therapeutic bone marrow transplants.

«New approaches to understand the immunology of graft - versus - host disease and limit its impact are urgently needed to improve the quality of life for our patients and increase their long term cancer - free survival.»

In some cases, the transplanted marrow launches an immune attack against the host's cells, a potentially lethal condition called graft - versus - host disease.

Bertani G, Santoleri L, Ferri U, Marenco P, Grillo G, Zucchetti E, Forno B, Lando G, Scarpati B, Cairoli R, Rossini S, Cesana C. Response of steroid - refractory chronic graft - versus - host disease to extracorporeal photopheresis correlates with the dose of CD3 + lymphocytes harvested during early treatment cycles.

The biggest drawback is about 50 % of elderly patients get graft - versus - host disease, which can be debilitating.

Hepatocyte growth factor ameliorates acute graft - versus - host disease and promotes hematopoietic function.

Vianello F, Dazzi F. Mesenchymal stem cells for graft - versus - host disease: a double edged sword?

But for blood cancer patients who receive donor hematopoietic stem cell transplants as part of their treatment, graft - versus - host disease (GVHD) often hampers their recovery.

Dr. Kitko had previous worked at the University of Michigan where she had developed a clinical and translational research focus in graft - versus - host disease.

Abbreviations: AD - MSC: adipose tissue derived mesenchymal stem cells; APC: antigen presenting cell; BM: bone marrow; CNI: calcineurin inhibitor; DC: dendritic cells; GVHD: graft - versus - host disease; HLA: histocompatibility locus antigen; HGF: hepatocyte growth factor; IL: interleukin; IDO: indoleamine 2,3 - dioxygenase; MLR: mixed lymphocyte reaction; MSC: mesenchymal stem cells; PGE2: prostaglandin E2; SC: stem cells; TGF: transforming growth factor; TH: T - helper; T - regs: T - regulatory cells.

For example, inhibiting OX40 / OX40L interactions can abrogate Th2 or Th1 / Th17 - induced pathologies in experimental leishmaniasis, EAE, graft - versus - host disease, transplantation, inflammatory bowel disease, asthma, and collagen - induced arthritis.

Manipulating the bioenergetics of alloreactive T cells causes their selective apoptosis and arrests graft - versus - host disease.

Histone deacetylase inhibition modulates indoleamine 2,3 - dioxygenase - dependent DC functions and regulates experimental graft - versus - host disease in mice.

Prior to joining CRI, Vanessa was a postdoctoral fellow at NYU School of Medicine, studying the role of a common gene variant and its effects on Graft - Versus - Host - Disease.

Low - dose donor CD8 + cells in the CD4 - depleted graft prevent allogeneic marrow graft rejection and severe graft - versus - host disease for chronic myeloid leukemia patients in first chronic phase.

The infusion of ex vivo activated and expanded CD4 (+) CD25 (+) immune regulatory cells inhibits graft - versus - host disease lethality.

Procedures include purging of cancerous cells and purifying donor stem cells to minimize graft - versus - host disease (a serious side effect related to the use of donor cells for transplant).